KBI Biopharma

Absci is a drug and target discovery company that leverages deep learning AI and synthetic biology to enhance the therapeutic potential of proteins. Its Integrated Drug Creation Platform streamlines the process of identifying novel drug targets, discovering optimal biotherapeutic candidates, and generating the necessary cell lines for manufacturing. By combining biologic drug discovery and cell line development into a single, efficient workflow, Absci collaborates with biotech and pharmaceutical innovators to develop next-generation protein-based drugs. These innovations include Bionic Proteins, which feature nonstandard amino acids, and other unique drug designs that may be unattainable through conventional methods. Absci's mission is to facilitate the development of improved medicines by effectively translating innovative ideas into viable drugs.

Absci is a drug and target discovery company that leverages deep learning AI and synthetic biology to enhance the therapeutic potential of proteins. Its Integrated Drug Creation Platform streamlines the process of identifying novel drug targets, discovering optimal biotherapeutic candidates, and generating the necessary cell lines for manufacturing. By combining biologic drug discovery and cell line development into a single, efficient workflow, Absci collaborates with biotech and pharmaceutical innovators to develop next-generation protein-based drugs. These innovations include Bionic Proteins, which feature nonstandard amino acids, and other unique drug designs that may be unattainable through conventional methods. Absci's mission is to facilitate the development of improved medicines by effectively translating innovative ideas into viable drugs.

Comera Life Sciences develops proprietary formulations for therapeutic biologics, enhancing their stability, efficiency, and administrability. Its patented technology enables drug companies to improve life-saving medicines.

Elion Labs is a contract services organization focused on meeting the analytical development and product characterization needs of the biopharmaceutical industry. The company provides a comprehensive range of services, including analytical method development, qualification, and validation, as well as analytical characterization testing of biologics. Elion also specializes in formulation development and offers training in advanced analytical techniques. Additionally, the company excels in comprehensive data analysis, which encompasses visualization and interpretation of complex data sets, along with technical and regulatory writing. Elion Labs is dedicated to delivering its services with a commitment to professionalism, quality, and efficiency.

GlycoSeLect develops Recombinant Prokaryotic Lectins (RPLs) as tools for the analysis and purification of glycosylated biomolecules. Its platform uses recombinant prokaryotic lectin chemistry to recognize and bind specific glycan structures on glycoproteins and other glycosylated biomolecules, enabling affinity-based approaches for glycan analysis and purification in biopharma product workflows. Applications span glycobiology and glycoproteomics, biomarker discovery and diagnostics, and the biopharmaceutical, vaccine, and cosmetics sectors. The RPLs offer advantages such as production in Escherichia coli, high purity and consistent performance, enhanced glycan-binding properties, and scalable manufacture for large-scale use.

Alliance Protein Laboratories, Inc. is a contract research and consulting firm based in San Diego, California, specializing in biophysical and biochemical analytical services for proteins, nucleic acids, and other macromolecular assemblies. Founded in 1998, the company provides a comprehensive array of services that include protein and peptide biophysical characterization, protein aggregation analysis, protein purification, and protein stabilization. Additionally, it offers advanced techniques such as analytical ultracentrifugation and concentration-gradient multi-angle light scattering. As of June 2018, Alliance Protein Laboratories operates as a subsidiary of KBI Biopharma Inc.

Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company based in Austin, Texas, specializing in the development of human enzyme therapeutics for rare genetic and cancer-related diseases. Founded in 2013, the company is focused on addressing unmet medical needs through innovative enzyme therapies. Its lead product candidate, pegzilarginase, is a recombinant human Arginase 1 enzyme currently undergoing a Phase III trial to assess its safety and efficacy in treating Arginase 1 deficiency. Additionally, Aeglea has a preclinical pipeline that includes several candidates targeting various metabolic disorders, such as ACN00177 for homocystinuria, AEB5100 for the degradation of plasma cystine and cysteine, and AEB2109, which focuses on methionine degradation. Aeglea BioTherapeutics aims to make significant advancements in the treatment of rare metabolic diseases through its specialized enzyme therapies.